Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC
Status:
Withdrawn
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
This is a single arm, open label, multi-center, phase 2 study to evaluate the safety and
efficacy of sequential treatment with Melphalan/HDS followed by sorafenib in patients with
unresectable hepatocellular carcinoma (HCC) confined to the liver.